Archon Biosciences logo

Archon Biosciences

archon.bio

Archon Biosciences develops geometrically tunable protein therapeutics called Antibody Cages (AbCs), which integrate antibody affinity and specificity with generative protein design to target pathways inaccessible to other technologies. Its platform uses AI-driven structural engineering to create biologics with precise control over distribution, engagement, and function for improved treatment of disease. The organization aims to solve challenging drug discovery problems by advancing new classes of biologic medicines.

Facts

HQ
Seattle, Washington, US
Sectors
Biotechnology Research
Type
Corporation Seattle business license
Employees
26
Registered name
Archon Biosciences Inc Seattle business license
Stage
Seed

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Archon Biosciences

See all 15

Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model

Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.

James Lazarovits - Co-Founder and CEO at Archon Biosciences

James Lazarovits is the CEO and Co-Founder of Archon Biosciences, a leader at the intersection of materials engineering and artificial intelligence. James brings over 15 years of experience building, mentoring, and investing in deep tech startups across AI, software, hardware, and robotics. Before founding Archon, James was at the forefront of AI-driven computational protein design as a post-doctoral fellow and later research faculty at the Institute for Protein Design at the University of Washington, under the direction of 2024 Nobel Laureate, David Baker. There, he contributed to pioneering methods that integrate machine learning and molecular engineering to create next-gen therapeutic…

People

  • George Ueda
    George Ueda Chief Technology Officer, Co-Founder
  • James Lazarovits Chief Executive Officer, Co-Founder

Online

Questions about Archon Biosciences

What is Archon Biosciences?

Archon Biosciences is a startup based in Seattle, Washington, US, that develops geometrically tunable protein therapeutics called Antibody Cages (AbCs). Its platform combines antibody affinity and specificity with AI-driven protein design to target pathways inaccessible to other technologies.

What has Archon Biosciences been in the news for?

A July 2025 story featured James Lazarovits as co-founder and CEO at Archon Biosciences.

Who are the people behind Archon Biosciences?

James Lazarovits is CEO and co-founder of Archon Biosciences. George Ueda is chief technology officer and co-founder.

Who invested in Archon Biosciences, and how much has it raised?

Members of Seattle Flow see Archon Biosciences' funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Archon Biosciences based?

Archon Biosciences is based in Seattle, Washington, US.

When was Archon Biosciences founded?

Archon Biosciences was founded in 2023.